Healthcare


 Kalkine | Healius Limited (ASX:HLS) Slides Sharply Amid Revenue Concerns and Broader ASX 200 Movements

Kalkine | Healius Limited (ASX:HLS) Slides Sharply Amid Revenue Concerns and Broader ASX 200 Movements

May 29, 2025 04:11 PM AEST| By Team Kalkine Media

Highlights,Healius Limited (ASX:HLS) declines amid ongoing revenue contraction and weak sentiment,Industry comparisons highlight pressure on valuation within the healthcare segment,ASX 200 benchmark shows mixed movements driven by varying sectoral pe...

 Emyria’s (ASX:EMD) Breakthrough PTSD Results and ANU Partnership Highlight Innovation in Mental Health Care

Emyria’s (ASX:EMD) Breakthrough PTSD Results and ANU Partnership Highlight Innovation in Mental Health Care

May 29, 2025 03:55 PM AEST| By Team Kalkine Media

Highlights,63% of PTSD patients showed no further diagnosis criteria,Emyria partners with ANU to develop mental health care models,Strong positioning in innovative ASX300 healthcare space,Emyria (ASX:EMD), a clinical-stage biotech company, has shared...

 Noxopharm's HERACLES Trial Receives Green Light, Boosting Momentum Within ASX300

Noxopharm's HERACLES Trial Receives Green Light, Boosting Momentum Within ASX300

May 29, 2025 03:42 PM AEST| By Team Kalkine Media

Highlights,HERACLES trial approved for SOF-SKN™ in Australia,Strategic focus on chronic inflammatory conditions,Operational setup begins with expert clinical team,Noxopharm Limited (ASX:NOX) has achieved a major milestone with the approval of its HER...

 ASX 200 Healthcare Spotlight: RMD Shares Trade Below Historical Multiples

ASX 200 Healthcare Spotlight: RMD Shares Trade Below Historical Multiples

May 29, 2025 03:08 PM AEST| By Team Kalkine Media

Highlights,ResMed CDI (ASX:RMD) operates within the healthcare sector and maintains a dual listing on the ASX and NYSE,RMD shares reflect a lower price-to-sales ratio compared to historical averages, supported by revenue growth,The company provides C...

 Invion’s INV043 Shows Promise in Skin Cancer Treatment as ASX200 Health Innovation Gains Momentum

Invion’s INV043 Shows Promise in Skin Cancer Treatment as ASX200 Health Innovation Gains Momentum

May 29, 2025 02:51 PM AEST| By Team Kalkine Media

Highlights,INV043 shows no adverse events in Phase I/II NMSC trial,Treatment highlights diagnostic potential through fluorescence,Phase II to refine treatment strategy with adjusted dosage,Australian biotech company Invion (ASX:IVX) has shared encour...

 EBOS Dips on Major Share Sale News – What It Means for the ASX200

EBOS Dips on Major Share Sale News – What It Means for the ASX200

May 29, 2025 02:40 PM AEST| By Team Kalkine Media

Highlights,EBOS shares fall after major shareholder divests stake,$881 million share block hits market sentiment,Stock remains part of ASX dividend stocks list,Shares of healthcare and pharmaceutical distributor,EBOS Group,(ASX:EBO) dropped sharply f...

 Clarity Pharmaceuticals (ASX:CU6) Progresses AMPLIFY Trial with First Patient Imaging, Boosting Prospects in ASX200

Clarity Pharmaceuticals (ASX:CU6) Progresses AMPLIFY Trial with First Patient Imaging, Boosting Prospects in ASX200

May 29, 2025 12:29 PM AEST| By Team Kalkine Media

Highlights,Clarity Pharmaceuticals (CU6) advances phase three trial for prostate cancer diagnosis,First patient imaged in AMPLIFY trial soon after study launch,Potential breakthrough in early detection of recurrent prostate cancer,Shares of Clarity P...

 Kalkine: Imugene (ASX:IMU) Schedules Key EGM to Decide on Share Consolidation and Capital Raise

Kalkine: Imugene (ASX:IMU) Schedules Key EGM to Decide on Share Consolidation and Capital Raise

May 27, 2025 03:22 PM AEST| By Team Kalkine Media

Highlights,Imugene (IMU) to host EGM on 26 June 2025,Shareholders to vote on consolidation and capital raising,Funds aimed at advancing key clinical programs,Imugene (ASX:IMU), a biotechnology company focused on innovative cancer immunotherapies, has...

 Kalkine: Neuren Pharmaceuticals Delivers Strong Growth and Expansion Plans Amid ASX200 Momentum

Kalkine: Neuren Pharmaceuticals Delivers Strong Growth and Expansion Plans Amid ASX200 Momentum

May 27, 2025 03:13 PM AEST| By Team Kalkine Media

Highlights,Neuren posts A$166 million record income,DAYBUE drives global expansion outlook,Promising clinical trials support future pipeline,Neuren Pharmaceuticals (ASX:NEU) has made headlines with a remarkable financial performance for the year 2024...

 Kalkine: PainChek Expands US Presence with Eldermark Partnership, Eyes Growth Ahead of ASX200 Inclusion

Kalkine: PainChek Expands US Presence with Eldermark Partnership, Eyes Growth Ahead of ASX200 Inclusion

May 27, 2025 01:22 PM AEST| By Team Kalkine Media

Highlights,PainChek,teams up with,Eldermark,to grow US market reach,Integration to deliver AI-driven pain assessments in real-time,FDA clearance to unlock full-scale sales rollout,PainChek (ASX:PCK),has entered a strategic partnership with Eldermark...

 Kalkine: Prescient Therapeutics (ASX:PTX) Advances Rare Blood Cancer Treatment with Phase 2a Trial Amid ASX200 Momentum

Kalkine: Prescient Therapeutics (ASX:PTX) Advances Rare Blood Cancer Treatment with Phase 2a Trial Amid ASX200 Momentum

May 27, 2025 12:42 PM AEST| By Team Kalkine Media

Highlights:,Phase 2a study initiated for PTX-100 in rare Cutaneous T-Cell Lymphoma,Trial spans Australia, US, and Europe with up to 40 patients,PTX-100 targets unmet need in relapsed or refractory CTCL,Prescient Therapeutics (ASX:PTX) has reached a s...

 ASX 200 Healthcare Giants: Performance Snapshot of CSL, SIG, PME, RMD, and FPH

ASX 200 Healthcare Giants: Performance Snapshot of CSL, SIG, PME, RMD, and FPH

May 26, 2025 05:26 PM AEST| By Team Kalkine Media

Highlights,CSL (ASX:CSL) shows modest gains while maintaining its leadership in biopharmaceuticals,SIG (ASX:SIG) continues to lead pharmacy distribution despite a slight decline,PME (ASX:PME) and RMD (ASX:RMD) experience minor pullbacks amid strong a...

 Healthscope’s Future in the ASX300: No Taxpayer Bailout, Government Confirms

Healthscope’s Future in the ASX300: No Taxpayer Bailout, Government Confirms

May 26, 2025 03:34 PM AEST| By Team Kalkine Media

Highlights,Government will not provide taxpayer bailout to Healthscope.,Patient care and hospital integrity remain top priorities.,Focus on orderly sale to protect all stakeholders.,The Australian Government has made it clear that Healthscope (ASX:HS...

 ASX 200 Healthcare Shock: ASX:CBA Supports Healthscope Amid Receivership

ASX 200 Healthcare Shock: ASX:CBA Supports Healthscope Amid Receivership

May 26, 2025 02:49 PM AEST| By Team Kalkine Media

Highlights,Healthscope enters voluntary receivership amid severe financial strain and debt concerns,Commonwealth Bank of Australia (ASX:CBA) offers financial support to maintain hospital operations,Landlords issue breach notices as tenancy defaults e...

 Recce Pharmaceuticals (ASX:RCE) Strengthens Patent Portfolio with Chinese Approval, Boosting Presence in ASX200 Pharma Sector

Recce Pharmaceuticals (ASX:RCE) Strengthens Patent Portfolio with Chinese Approval, Boosting Presence in ASX200 Pharma Sector

May 26, 2025 12:57 PM AEST| By Team Kalkine Media

Highlights,Recce secures patent approval in China for key anti-infective drug candidates.,Patent covers multiple bacterial and viral infections with varied administration methods.,Expansion enhances Recce’s global intellectual property footprint in m...

 Which Healthcare Leader in the S&P/ASX Two Hundred and ASX All Ordinaries Tops Global Fund Holdings?

Which Healthcare Leader in the S&P/ASX Two Hundred and ASX All Ordinaries Tops Global Fund Holdings?

May 23, 2025 06:18 PM AEST| By Team Kalkine Media

Which Healthcare Leader in the S&P/ASX Two Hundred and ASX All Ordinaries Tops Global Fund Holdings?

 ASX 200 Health Stocks Climb Amid Capital Raisings and Diagnostic Advancements

ASX 200 Health Stocks Climb Amid Capital Raisings and Diagnostic Advancements

May 23, 2025 04:31 PM AEST| By Team Kalkine Media

Highlights:,Multiple ASX-listed healthcare firms initiate capital raisings to strengthen cash positions,EMVision showcases improved stroke diagnostic performance using AI at major health conference,Monash IVF updates FY25 outlook following operationa...

 Mayne Pharma (ASX:MYX) Shares Show Partial Rebound Amid Takeover Uncertainty and ASX200 Volatility

Mayne Pharma (ASX:MYX) Shares Show Partial Rebound Amid Takeover Uncertainty and ASX200 Volatility

May 23, 2025 02:41 PM AEST| By Team Kalkine Media

Highlights,Mayne Pharma shares recover after sharp weekly decline,FDA concerns impact takeover negotiations with US firm Cosette,Market watchers eye implications for ASX dividend stocks and ASX200,Mayne Pharma (ASX:MYX) shares experienced a partial r...

 Hengrui’s Soaring Hong Kong Debut Sparks Optimism Across ASX200 and Global Pharma Markets

Hengrui’s Soaring Hong Kong Debut Sparks Optimism Across ASX200 and Global Pharma Markets

May 23, 2025 12:27 PM AEST| By Team Kalkine Media

Highlights,Hengrui jumps 29% in Hong Kong listing,$2 billion capital to fuel drug innovation,Market buzz adds momentum to ASX200,In a remarkable debut that has stirred enthusiasm among global investors,,Jiangsu Hengrui Pharmaceuticals (HKG:600276),,...

 Nyrada’s Breakthrough TRPC Blocker Gains Momentum in ASX200 Medical Research Space

Nyrada’s Breakthrough TRPC Blocker Gains Momentum in ASX200 Medical Research Space

May 23, 2025 12:00 AM AEST| By Team Kalkine Media

Highlights,Drug shows promise for stroke, heart attack, and brain injury,Early trial data confirms safety and strong tissue preservation,Anti-arrhythmic effects observed in follow-up studies,Nyrada Inc. (ASX:NYR) has reported encouraging progress on...

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles






Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.